Article Sidebar
Main Article Content
Abstract
Background: Amyotrophic lateral sclerosis is a rapidly progressive, fatal neurodegenerative disorder characterized by the deterioration of upper and lower motor neurons. Diagnostic delays are frequently caused by phenotypic overlap with various mimic disorders. Serum neurofilament light chain has emerged as a promising biomarker; however, its precise discriminatory capacity against mimics and its utility in predicting disease trajectory necessitate rigorous quantitative evaluation.
Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic search of MEDLINE/PubMed, Embase, Cochrane Central, and Scopus was conducted. Eight high-quality primary research articles met the strict inclusion criteria for data extraction. Studies evaluating diagnostic utility (amyotrophic lateral sclerosis versus mimic disorders) and prognostic value (survival hazard ratios) were included. Random-effects models calculated pooled standardized mean differences for diagnostic accuracy and pooled hazard ratios for overall survival.
Results: The meta-analysis analyzed data from 8 cohorts. Serum neurofilament light chain levels were significantly elevated in amyotrophic lateral sclerosis patients compared to mimic disorders, yielding a pooled standardized mean difference of 1.43 (95% confidence interval: 1.15 to 1.71, p < 0.001). High heterogeneity was observed (I-squared = 82%). For prognostic evaluation, a pilot quantitative synthesis of two cohorts demonstrated that higher baseline concentrations correlated with increased mortality risk, showing a pooled hazard ratio of 1.95 (95% confidence interval: 1.58 to 2.41, p < 0.001).
Conclusion: Serum neurofilament light chain is a robust discriminatory biomarker capable of distinguishing amyotrophic lateral sclerosis from confounding mimic disorders. Furthermore, baseline concentrations offer prognostic value for survival outcomes. These findings support the cautious integration of this biomarker into clinical algorithms, though broader multi-center prognostic studies are required.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
